To Assess the Effectiveness of Caffeine Consumption as a Potential Therapeutic Intervention for Parkinson’s Disease: A Systematic Review
DOI:
https://doi.org/10.61173/c3wm3r65Keywords:
systematic review, effectiveness, motor, cognitive, neuroprotective effects, therapeutic, caffeine, Parkinson’s diseaseAbstract
The second most prevalent neurodegenerative disease, Parkinson's disease (PD), requires new approaches because there are currently no disease-modifying therapies. This systematic review evaluates the therapeutic potential of caffeine consumption for PD, focusing on the alleviation of motor and cognitive symptoms as well as potential neuroprotective mechanisms. Utilizing PubMed and Google Scholar, initially, 12,187 articles (2015-2025) were screened, with five clinical trials meeting the inclusion criteria (full-text, English, human or animal studies). Results indicated mixed outcomes: higher cognitive performance in low-demand activities [1] and improved motor function (e.g., lower UPDRS-III scores [2] were associated with low-dose caffeine (<400 mg/day). Inhibition of adenosine A2A and MAO-B receptors was linked to neuroprotective benefits, including reduced alpha-synuclein toxicity and neuroinflammation [3, 4]. However, conflicting studies reported negligible benefits [5] or dose-dependent risks [6]. Small sample sizes, methodological variability, and reliance on animal models were among the limitations that raised concerns regarding reliability. Caffeine shows potential in reducing Parkinson's disease symptoms by blocking A2A receptors and influencing oxidative pathways, but inconsistent findings highlight the necessity for large-scale human trials and standardised dosage recommendations. Caffeine's potential as an adjuvant therapy is highlighted by these findings, although caution is advised because individual variations and safety implications are still unknown. Further research is essential to establish the optimal therapeutic strategies and long-term success in the management of Parkinson's disease.
References
[1] Sharma, K., Fallon, S.J., Davis, T., Ankrett, S., Munro, G., Christopher, G. and Coulthard, E. (2022). Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson’s disease according to task demands. Psychopharmacology, [online] 239(2), pp.605–619. doi:https://doi.org/10.1007/s00213-021-06054-9.
[2] Hamdan, M., Suharto, A.P., Priya Nugraha and Islamiyah, W.R. (2024). Motor improvement in Parkinson’s disease patients receiving caffeine adjuvants: A double-blind randomized controlled trial in Indonesia. Narra J, [online] 4(2), pp.e826– e826. doi:https://doi.org/10.52225/narra.v4i2.826.
[3] Machado, D.G., Vinicius, M., Dobler, P.B., Almeida, R.F. and Porciúncula, L.O. (2019). Caffeine prevents neurodegeneration and behavioral alterations in a mice model of agitated depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 98, pp.109776–109776. doi:https:// doi.org/10.1016/j.pnpbp.2019.109776.
[4] Boulaamane, Y., Ibrahim, M.A.A., Britel, M.R. and Maurady, A. (2022). In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA2AR antagonists for the treatment of Parkinson’s disease. Journal of Integrative Bioinformatics, [online] 19(4), p.20210027. doi:https://doi. org/10.1515/jib-2021-0027.
[5] Postuma, R.B., Lang, A.E., Munhoz, R.P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Rios Romenets, S., Altman, R., Chuang, R. and Shah, B. (2012). Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology, [online] 79(7), pp.651–658. doi:https://doi.org/10.1212/WNL.0b013e318263570d.
[6] Ascherio, A., Chen, H., Schwarzschild, M.A., Zhang, S.M., Colditz, G.A. and Speizer, F.E. (2003). Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology, [online] 60(5), pp.790–795. doi:https://doi.org/10.1212/01. wnl.0000046523.05125.87.
[7] Kouli, A., Torsney, K.M. and Kuan, W.-L. (2018). Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson’s Disease: Pathogenesis and Clinical Aspects, [online] 1(1), pp.3–26. doi:https://doi.org/10.15586/ codonpublications.parkinsonsdisease.2018.ch1.
[8] Dorsey, E.R., Sherer, T., Okun, M.S. and Bloem, B.R. (2018). The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson’s Disease, 8(s1), pp.S3–S8. doi:https://doi. org/10.3233/jpd-181474.
[9] Kalia, L.V. and Lang, A.E. (2015). Parkinson’s disease. The Lancet, [online] 386(9996), pp.896–912. doi:https://doi. org/10.1016/s0140-6736(14)61393-3.
[10] Jankovic, J. and Tan, E.K. (2020). Parkinson’s Disease: Etiopathogenesis and Treatment. Journal of Neurology, Neurosurgery & Psychiatry, [online] 91(8), pp.795–808. doi:https://doi.org/10.1136/jnnp-2019-322338.
[11] Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H.R. and Foltynie, T. (2021). Progress towards therapies for disease modification in Parkinson’s disease. The Lancet Neurology, Dean&Francis ISSN 2959-409X 20(7), pp.559–572. doi:https://doi.org/10.1016/s1474- 4422(21)00061-2.
[12] Barcelos, R.P., Lima, F.D., Carvalho, N.R., Bresciani, G. and Royes, L.F. (2020). Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance. Nutrition Research, [online] 80(1), pp.1–17. doi:https://doi.org/10.1016/j.nutres.2020.05.005.
[13] Zhao, L., Wei, J., Hu, Y., Pi, D., Jiang, M. and Lang, T. (2023). Caffeine Synthesis and Its Mechanism and Application by Microbial Degradation, A Review. Foods, 12(14), pp.2721– 2721. doi:https://doi.org/10.3390/foods12142721.
[14] Ren, X. and Chen, J.-F. (2020). Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms. Frontiers in Neuroscience, 14. doi:https://doi.org/10.3389/ fnins.2020.602697.
[15] McGregor, M.M. and Nelson, A.B. (2019). Circuit Mechanisms of Parkinson’s Disease. Neuron, [online] 101(6), pp.1042–1056. doi:https://doi.org/10.1016/j.neuron.2019.03.004.
[16] Raza, C., Anjum, R. and Shakeel, N. ul A. (2019). Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sciences, 226, pp.77–90. doi:https:// doi.org/10.1016/j.lfs.2019.03.057.
[17] John Hopkins Medicine (2022). Lewy Body Dementia (LBD). [online] www.hopkinsmedicine.org. Available at: https:// www.hopkinsmedicine.org/health/conditions-and-diseases/ dementia/dementia-with-lewy-bodies.
[18] Butler, B., Sambo, D. and Khoshbouei, H. (2017). Alphasynuclein modulates dopamine neurotransmission. Journal of Chemical Neuroanatomy, [online] 83-84, pp.41–49. doi:https:// doi.org/10.1016/j.jchemneu.2016.06.001.
[19] Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G. and Ghiglieri, V. (2023). Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death & Disease, [online] 14(3), pp.1–16. doi:https://doi. org/10.1038/s41419-023-05672-9.
[20] Sonne, J., Reddy, V. and Beato, M.R. (2022). Neuroanatomy, Substantia Nigra. [online] PubMed. Available at: https://www. ncbi.nlm.nih.gov/books/NBK536995/#.
[21] Chen, J.-F. ., Fredduzzi, S., Bastia, E., Yu, L., Moratalla, R., Ongini, E. and Schwarzschild, M.A. (2003). Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson’s disease. Neurology, 61(Issue 11, Supplement 6), pp.S74–S81. doi:https://doi.org/10.1212/01. wnl.0000095218.26363.7b.
[22] Riederer, P. and Laux, G. (2011). MAO-inhibitors in Parkinson’s Disease. Experimental Neurobiology, [online] 20(1), p.1. doi:https://doi.org/10.5607/en.2011.20.1.1.
[23] NHS Devon Clinical Effectiveness team and Devon Referral Support Services (n.d.). 4.9.1 Dopaminergic drugs used in Parkinson’s disease. [online] South & West. Available at: https://southwest.devonformularyguidance.nhs.uk/formulary/ chapters/4-central-nervous-system/4-9-drugs-used-inparkinsonism-and-related-disorders/4-9-1-dopaminergic-drugsused-in-parkinsons-disease.
[24] Alonso Cánovas, A., Luquin Piudo, R., García Ruiz-Espiga, P., Burguera, J.A., Campos Arillo, V., Castro, A., Linazasoro, G., López Del Val, J., Vela, L. and Martínez Castrillo, J.C. (2014). Dopaminergic agonists in Parkinson’s disease. Neurología (English Edition), [online] 29(4), pp.230–241. doi:https://doi. org/10.1016/j.nrleng.2011.04.010.
[25] DRUGBANK (2021). Levodopa. [online] go.drugbank. com. Available at: https://go.drugbank.com/drugs/DB01235.
[26] Müller, T. (2012). Drug therapy in patients with Parkinson’s disease. Translational Neurodegeneration, 1(1), p.10. doi:https:// doi.org/10.1186/2047-9158-1-10.
[27] The Parkinson Study Group (2004). Levodopa and the Progression of Parkinson’s Disease. New England Journal of Medicine, [online] 351(24), pp.2498–2508. doi:https://doi. org/10.1056/nejmoa033447.
[28] Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M.J., Mouradian, M.M. and Chase, T.N. (2003). Adenosine A2A receptor antagonist treatment of Parkinson’s disease. Neurology, [online] 61(3), pp.293–296. doi:https://doi.org/10.1212/01.WNL.0000073136.00548.D4.
[29] Willson, C. (2018). The clinical toxicology of caffeine: A review and case study. Toxicology Reports, 5, pp.1140–1152. doi:https://doi.org/10.1016/j.toxrep.2018.11.002.
[30] Temple, J.L., Bernard, C., Lipshultz, S.E., Czachor, J.D., Westphal, J.A. and Mestre, M.A. (2017). The safety of ingested caffeine: A comprehensive review. Frontiers in Psychiatry, [online] 8(80). doi:https://doi.org/10.3389/fpsyt.2017.00080.
[31] Eleazar Ramírez Hernández, Olvera, B.A., González, D.C., Marín, O.G., Mercado, D.P., Gil, L.V., Hernández- Zimbrón, L.F., Sánchez, L., I. Daniel Limón and Zenteno, E. (2022). Neuroinflammation and galectins: a key relationship in neurodegenerative diseases. Glycoconjugate Journal, 39(5), pp.685–699. doi:https://doi.org/10.1007/s10719-022-10064-w.
[32] Skaper, S.D., Facci, L., Zusso, M. and Giusti, P. (2018). An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Frontiers in Cellular Neuroscience, [online] 12. doi:https://doi.org/10.3389/fncel.2018.00072.
[33] Dutta, G., Zhang, P. and Liu, B. (2008). The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundamental & Clinical Pharmacology, 22(5), pp.453–464. doi:https://doi.org/10.1111/ j.1472-8206.2008.00616.x.
[34] Badshah, H., Ikram, M., Ali, W., Ahmad, S., Hahm, J.R. and Kim, M.O. (2019). Caffeine May Abrogate LPS-Induced Oxidative Stress and Neuroinflammation by Regulating Nrf2/ TLR4 in Adult Mouse Brains. Biomolecules, [online] 9(11), p.719. doi:https://doi.org/10.3390/biom9110719.
[35] Checkoway, H., Powers, K., Smith-Weller, T., Franklin, Dean&Francis Xinyi Gao G.M., Longstreth, W.T. and Swanson, P.D. (2002). Parkinson’s Disease Risks Associated with Cigarette Smoking, Alcohol Consumption, and Caffeine Intake. American Journal of Epidemiology, [online] 155(8), pp.732–738. doi:https://doi. org/10.1093/aje/155.8.732.
[36] Ferreira, J.J., Mestre, T., Leonor Correia Guedes, Coelho, M., Rosa, M.M., Santos, A.T., Barra, M., Sampaio, C. and Rascol, O. (2016). Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease: Results of n-of-1 Trials. Frontiers in Neurology, 7. doi:https://doi.org/10.3389/ fneur.2016.00027.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
